Randomized cross-over trial comparing inpatient and outpatient administration of high-dose cisplatin

Internal Medicine Journal

Volumn 41, Issue 2, 2011, Pages 172-178

  Cox, K M ^a   Goel, S ^a   O'Connell, R L ^b   Boyer, M ^a   Beale, P J ^a,c   Simes, R J ^a,b   Stockler, M R ^a,b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ANZAC Research Institute   (Australia)

Author keywords

Cisplatin; Health services; Inpatient; Outpatient; Patient preference

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CROSSOVER PROCEDURE; DEPRESSION; DRUG MEGADOSE; FATIGUE; FEMALE; FEVER; HOSPITAL PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTPATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADULT; AMBULATORY CARE; CISPLATIN; CROSS-OVER STUDIES; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PATIENT PREFERENCE;

EID: 79952020135     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02201.x     Document Type: Article

References (17)

1. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS etal. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985; 3: 1379-84.
2. Madias NE, Harrington JT. Platinum nephrotoxicity. Am J Med 1978; 65: 307-14.
3. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R etal. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-19.
4. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977; 39: 1372-81.
5. de Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ etal. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 2003; 88: 1199-206.
6. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 2008; 73: 994-1007.
7. Rubenstein EB. Costs and benefits of outpatient therapy. Support Care Cancer 1994; 2: 307-11.
8. Magid DM, Vokes EE, Schilsky RL, Guarnieri CM, Whaling SM, Weichselbaum RR etal. A randomized study of inpatient versus outpatient continuous intravenous infusion chemotherapy: psychosocial aspects. Sel Cancer Ther 1989; 5: 137-45.
9. Coates A, Glasziou P, McNeil D. On the receiving end - III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1990; 1: 213-17.
10. Martin AJ, Gratorex V, Simes RJ. Towards a utility-based assessment for cancer patients: reliability and validity of the UBQ-C(ancer) items. Control Clin Trials 1997; 18: 160S.
11. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol 1979; 8: 7-20.
12. Grusenmeyer PA, Gralla RJ, Trapani MM, Bateman MM. Alternatives to inpatient care: a cost comparison of home versus outpatient clinic care for chemotherapy administration and supportive care measures (abstract). American Society of Clinical Oncology Annual Meeting, 1996; Abstr 926.
13. Lavola A, Danel S, Gounant V, Epaud C, Rosencher L, Wislez M etal. Safe and rapid outpatient administration of cisplatin >75mg/m2 for lung cancer. J Clin Oncol 2008; 26 (May 20 suppl): abstr 20737.
14. Stathopoulos GP, Malamos NA, Papakostas P, Moschopoulos N, Samelis GF, Michailakis E. Treatment of non-small cell lung cancer with cisplatin combination on an outpatient basis. Effectiveness, toxicity and cost benefit. American Society of Clinical Oncology Annual Meeting, 1995; Abstr 1181.
15. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer 1994; 2: 161-6.
16. Vokes EE, Schilsky RL, Choi KE, Magid DM, Guarnieri CM, Whaling SM etal. A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer 1989; 63: 30-6.
17. Rose PG, Lappas PT. Analysis of the cost effectiveness of concurrent cisplatin-based chemoradiation in cervical cancer: implications from five randomized trials. Gynecol Oncol 2000; 78: 3-6.